Dexbrompheniramine-Fluphenazine in the Management of Pruritus: Comparison With Methdilazine

¹ Emory University Clinic, Department of Internal Medicine, Atlanta, Ga.

In a double-blind cross-over study of 102 patients with chronic pruritic dermatoses, dexbrompheniramine-fluphenazine (Diperm® Chronotab) showed consistent and significantly greater efficacy in the oral management of pruritus than did methdilazine (Tacaryl). Excellent remission of pruritus in patients on dexbrompheniramine-fluphenazine was observed nearly three times as often as that noted in patients on methdilazine. Excellent and good remissions of pruritus, combined, were observed approximately one-third more frequently in patients on dexbrompheniramine-fluphenazine than in those on methdilazine.

Side effects, consisting mostly of drowsiness, were noted in 7 per cent of patients on dexbrompheniramine-fluphenazine as compared to 45 per cent of the patients on methdilazine. It appears that dexbrompheniramine-fluphenazine would be a more useful adjunct in the management of pruritic dermatoses than methdilazine.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?